Clinical Trial Update: Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 study of NP-G2-044, a metastasis inhibitor, in patients with advanced or metastatic treatment-refractory solid tumors has completed, with multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Esophageal Cancer
• Liver Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• NP-G2-044

Snippet

Sponsor: Novita Pharmaceuticals, Inc. | Conditions: Breast Cancer, Pancreas Cancer | Phase 1 | Status: COMPLETED